PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee osteoarthritis, an external post hoc analysis of Phase 3 data showed JTA-004 is safe and efficient for treating pain symptoms in the most severely affected patients. Mont-Saint-Guibert, Belgium, January 25 2024, 7.00 am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company speci
Related Keywords
Vienna , Wien , Austria , France , Mont Saint Guibert , Waals Gewest , Belgium , Paris , France General , French , Ghislaine Gasparetto , Carole Nicco , Yves Henrotin , Michelle Boxall , Ib Communications , Osteoarthritis Research Society International , World Congress , Interdisciplinary Research On Medicine , International Media Enquiries , Biosenic Group , University Of Li , Euronext Brussels , Interdisciplinary Research , Biosenic Chief Scientific Officer , Chief Operating , Rheum Dis Feb , Louvain La Neuve Science Park , Media Enquiries , French Investor Enquiries , Post Hoc Analysis , Inflammatory Diseases , Arsi World Congress , Osteoarthritis ,
comparemela.com © 2020. All Rights Reserved.